

**Mississippi Division Of Medicaid**  
**Provider Notice of Preferred Drug List Changes**  
**P&T Meeting Date: May 12, 2026**  
**PDL Changes Effective Date: July 1, 2026**



The following changes will be made to the Preferred Drug List (PDL), effective July 1, 2026, pending approval by the P&T Committee, DOM, and DOM's Executive Director.

<b>NEW PREFERRED DRUGS</b>	
<b>THERAPEUTIC CLASS</b>	<b>RECOMMENDED for PREFERRED STATUS</b>
Antineoplastics Selected Systemic Enzyme Inhibitors	<b>Ensacove</b> (ensartinib hydrochloride)
Antiobesity Select Agents	<b>Foundayo</b> (orforglipron)
Antiobesity Select Agents	<b>Zepbound</b> (tirzepatide)
Bone Resorption Suppression and Related Agents, Others	<b>Enoby</b> (denosumab-qbde)
Bone Resorption Suppression and Related Agents, Others	<b>Xtrenbo</b> (denosumab-qbde)
Hypoglycemics, Incretin Mimetics/Enhancers	<b>Mounjaro</b> (tirzepatide)

<b>NEW NON-PREFERRED DRUGS</b>	
<b>THERAPEUTIC CLASS</b>	<b>RECOMMENDED for NON-PREFERRED STATUS</b>
Analgesics, Opioid-Short Acting	<b>Xyvona</b> (levorphanol)
Anticonvulsants, Adjuvants	<b>perampanel</b>
Antineoplastics Selected Systemic Enzyme Inhibitors	<b>Komzifti</b> (ziftomenib)
Antiretrovirals, NNRTIs	<b>rilpivirine</b>
Bronchodilators and COPD Agents, Anticholinergics and COPD Agents	<b>ipratropium HFA</b>
Calcium Channel Blockers, Long-Acting	<b>Sdamlo</b> (amlodipine)
Calcium Channel Blockers, Short-Acting	<b>Cardamyst</b> (etripamil)
Cephalosporins and Related Antibiotics (Oral), Cephalosporins Third Generation	<b>cefixime tablet</b>
Fibromyalgia/Neuropathic Pain Agents	<b>milnacipran</b>

**Mississippi Division Of Medicaid**  
**Provider Notice of Preferred Drug List Changes**  
**P&T Meeting Date: May 12, 2026**  
**PDL Changes Effective Date: July 1, 2026**



<b>NEW NON-PREFERRED DRUGS</b>	
<b>THERAPEUTIC CLASS</b>	<b>RECOMMENDED for NON-PREFERRED STATUS</b>
Glucocorticoids (Inhaled)	<b>beclomethasone</b>
Immune Globulins	<b>Gammagard ERC</b> (immune globulin infusion (human))
Immune Globulins	<b>Qivigy</b> (immune globulin intravenous human-kthm)
Miscellaneous Brand/Generic, Miscellaneous	<b>Myqorzo</b> (aficamten)
Miscellaneous Brand/Generic, Familial Chylomicronemia Syndrome	<b>Redemplo</b> (plozasiran sodium)
NSAIDs, COX II Selective	<b>Zybic</b> (meloxicam)
NSAIDs, Non-Selective	<b>Orudis</b> (ketoprofen)
Ophthalmic Agents, Antibiotics	<b>besifloxacin</b>
Ophthalmic Agents, Antibiotic-Steroid Combinations	<b>tobramycin/loteprednol</b>
Stimulants and Related Agents, Long-Acting	<b>Arynta</b> (lisdexamfetamine)